AlzeCure Pharma Cash Flow Conversion Efficiency
AlzeCure Pharma cash flow conversion efficiency. Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has a cash flow conversion efficiency ratio of -0.150x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.62 Million ≈ $-819.93K USD) by net assets (Skr50.66 Million ≈ $5.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AlzeCure Pharma (2017–2024)
Cash flow conversion efficiency of AlzeCure Pharma from 2017 to 2024. This chart illustrates how AlzeCure Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for AlzeCure Pharma for real-time trading data and today's change.
AlzeCure Pharma Cash Flow Conversion Ratio Explained
AlzeCure Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AlzeCure Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AlzeCure Pharma ranked by their cash flow conversion efficiency. Also see how much is AlzeCure Pharma worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Everest Industries Limited
NSE:EVERESTIND
|
-0.034x |
|
Velan Inc.
TO:VLN
|
-0.110x |
|
Daehan Green Power Corporation
KQ:060900
|
-0.002x |
|
Ribbon Acquisition Corp Unit
NASDAQ:RIBBU
|
-0.001x |
|
KCC Engineering & Construction Co. Ltd
KQ:021320
|
-0.047x |
|
Brompton Lifeco Split Corp
TO:LCS
|
-0.005x |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
-0.023x |
|
Clipan Finance Indonesia Tbk
JK:CFIN
|
0.093x |
Annual Cash Flow Conversion Efficiency for AlzeCure Pharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of AlzeCure Pharma from 2017 to 2024. Review ALZCUR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr26.18 Million ≈ $2.82 Million |
Skr-35.12 Million ≈ $-3.78 Million |
-1.341x | -1143.15% |
| 2023-12-31 | Skr23.77 Million ≈ $2.56 Million |
Skr3.06 Million ≈ $328.98K |
0.129x | +107.78% |
| 2022-12-31 | Skr60.48 Million ≈ $6.51 Million |
Skr-99.91 Million ≈ $-10.75 Million |
-1.652x | +22.89% |
| 2021-12-31 | Skr32.97 Million ≈ $3.55 Million |
Skr-70.64 Million ≈ $-7.60 Million |
-2.142x | -241.35% |
| 2020-12-31 | Skr110.75 Million ≈ $11.92 Million |
Skr-69.51 Million ≈ $-7.48 Million |
-0.628x | -127.15% |
| 2019-12-31 | Skr182.01 Million ≈ $19.59 Million |
Skr-50.28 Million ≈ $-5.41 Million |
-0.276x | -77.59% |
| 2018-12-31 | Skr233.17 Million ≈ $25.09 Million |
Skr-36.27 Million ≈ $-3.90 Million |
-0.156x | +4.26% |
| 2017-12-31 | Skr51.83 Million ≈ $5.58 Million |
Skr-8.42 Million ≈ $-906.23K |
-0.162x | -- |
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more